US 11,666,631 B2
DPEP-1 binding compositions and methods of use
Stephen Mark Robbins, Calgary (CA); Donna Lorraine Senger, Calgary (CA); Jennifer Joy Rahn, Calgary (CA); Arthur Wing Sze Lau, Calgary (CA); Daniel Abraham Muruve, Calgary (CA); Saurav Roy Choudhury, Calgary (CA); Liane Babes, Calgary (CA); and Paul Kubes, Calgary (CA)
Assigned to Arch Biopartners, Inc., Toronto (CA)
Filed by Arch Biopartners, Inc., Toronto (CA)
Filed on Jul. 8, 2019, as Appl. No. 16/504,909.
Application 16/504,909 is a continuation of application No. 15/234,521, filed on Aug. 11, 2016, granted, now 10,493,127.
Claims priority of provisional application 62/264,032, filed on Dec. 7, 2015.
Claims priority of provisional application 62/203,704, filed on Aug. 11, 2015.
Prior Publication US 2020/0078442 A1, Mar. 12, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/17 (2006.01); A61P 43/00 (2006.01); A61P 37/06 (2006.01); A61P 13/12 (2006.01); A61P 29/00 (2006.01); A61P 35/04 (2006.01); A61K 9/00 (2006.01); A61K 31/662 (2006.01); A61K 31/664 (2006.01); A61K 38/08 (2019.01); A61K 38/10 (2006.01); A61K 38/55 (2006.01); C07C 323/58 (2006.01); C07F 9/30 (2006.01); C07K 16/40 (2006.01); C12N 9/48 (2006.01)
CPC A61K 38/1709 (2013.01) [A61K 9/0019 (2013.01); A61K 31/662 (2013.01); A61K 31/664 (2013.01); A61K 38/08 (2013.01); A61K 38/10 (2013.01); A61K 38/55 (2013.01); A61P 13/12 (2018.01); A61P 29/00 (2018.01); A61P 35/04 (2018.01); A61P 37/06 (2018.01); A61P 43/00 (2018.01); C07C 323/58 (2013.01); C07F 9/302 (2013.01); C07K 16/40 (2013.01); C12N 9/485 (2013.01); C12Y 304/13019 (2013.01); C07K 2317/76 (2013.01)] 20 Claims
 
1. A method for treating or preventing (i) acute kidney injury or (ii) ischemia-reperfusion injury in a subject in need thereof, comprising administering an effective amount of a compound that binds to DPEP-1 to the subject in the absence of an antibiotic or nephrotoxic compound, thereby treating or preventing the acute kidney injury or ischemia reperfusion injury.